FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213698701> ?p ?o ?g. }

• W3213698701 endingPage "5775" @default.
• W3213698701 startingPage "5775" @default.
• W3213698701 abstract "Pancreatic cancers are classified based on where they occur, and are grouped into those derived from exocrine and those derived from neuroendocrine tumors, thereby experiencing different anticancer effects under medication. Therefore, it is necessary to develop anticancer drugs that can inhibit both types. To this end, we developed a heparin-taurocholate conjugate, i.e., LHT, to suppress tumor growth via its antiangiogenic activity. Here, we conducted a study to determine the anticancer efficacy of LHT on pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (PNET), in an orthotopic animal model. LHT reduced not only proliferation of cancer cells, but also attenuated the production of VEGF through ERK dephosphorylation. LHT effectively reduced the migration, invasion and tube formation of endothelial cells via dephosphorylation of VEGFR, ERK1/2, and FAK protein. Especially, these effects of LHT were much stronger on PNET (RINm cells) than PDAC (PANC1 and MIA PaCa-2 cells). Eventually, LHT reduced ~50% of the tumor weights and tumor volumes of all three cancer cells in the orthotopic model, via antiproliferation of cancer cells and antiangiogenesis of endothelial cells. Interestingly, LHT had a more dominant effect in the PNET-induced tumor model than in PDAC in vivo. Collectively, these findings demonstrated that LHT could be a potential antipancreatic cancer medication, regardless of pancreatic cancer types." @default.
• W3213698701 created "2021-11-22" @default.
• W3213698701 creator A5030752637 @default.
• W3213698701 creator A5032796168 @default.
• W3213698701 creator A5042365463 @default.
• W3213698701 creator A5046565682 @default.
• W3213698701 creator A5068708618 @default.
• W3213698701 creator A5078667650 @default.
• W3213698701 creator A5085655794 @default.
• W3213698701 date "2021-11-18" @default.
• W3213698701 modified "2023-10-04" @default.
• W3213698701 title "Anticancer Effect of Heparin–Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer" @default.
• W3213698701 cites W1492549565 @default.
• W3213698701 cites W1495287184 @default.
• W3213698701 cites W1562216431 @default.
• W3213698701 cites W1579297325 @default.
• W3213698701 cites W1924698819 @default.
• W3213698701 cites W1931508686 @default.
• W3213698701 cites W1970107343 @default.
• W3213698701 cites W1975501741 @default.
• W3213698701 cites W1983376387 @default.
• W3213698701 cites W1985187690 @default.
• W3213698701 cites W1991463736 @default.
• W3213698701 cites W1993185745 @default.
• W3213698701 cites W2002078725 @default.
• W3213698701 cites W2002859729 @default.
• W3213698701 cites W2007663426 @default.
• W3213698701 cites W2009337734 @default.
• W3213698701 cites W2011582582 @default.
• W3213698701 cites W2016957737 @default.
• W3213698701 cites W2019810971 @default.
• W3213698701 cites W2020713728 @default.
• W3213698701 cites W2021548785 @default.
• W3213698701 cites W2024157250 @default.
• W3213698701 cites W2027306348 @default.
• W3213698701 cites W2028307915 @default.
• W3213698701 cites W2028939316 @default.
• W3213698701 cites W2030378348 @default.
• W3213698701 cites W2047782887 @default.
• W3213698701 cites W2050771323 @default.
• W3213698701 cites W2052289281 @default.
• W3213698701 cites W2058727554 @default.
• W3213698701 cites W2067205052 @default.
• W3213698701 cites W2070208294 @default.
• W3213698701 cites W2074736160 @default.
• W3213698701 cites W2076216271 @default.
• W3213698701 cites W2083590898 @default.
• W3213698701 cites W2085254701 @default.
• W3213698701 cites W2086055645 @default.
• W3213698701 cites W2087568374 @default.
• W3213698701 cites W2088315853 @default.
• W3213698701 cites W2091532737 @default.
• W3213698701 cites W2106361417 @default.
• W3213698701 cites W2107441200 @default.
• W3213698701 cites W2108623236 @default.
• W3213698701 cites W2112578787 @default.
• W3213698701 cites W2120895512 @default.
• W3213698701 cites W2126517766 @default.
• W3213698701 cites W2136339421 @default.
• W3213698701 cites W2138321048 @default.
• W3213698701 cites W2140241614 @default.
• W3213698701 cites W2148748525 @default.
• W3213698701 cites W2151637779 @default.
• W3213698701 cites W2151898186 @default.
• W3213698701 cites W2152538957 @default.
• W3213698701 cites W2162818672 @default.
• W3213698701 cites W2168278545 @default.
• W3213698701 cites W2168992025 @default.
• W3213698701 cites W2189555626 @default.
• W3213698701 cites W2338354883 @default.
• W3213698701 cites W2395037329 @default.
• W3213698701 cites W2530292833 @default.
• W3213698701 cites W2773643777 @default.
• W3213698701 cites W2888299795 @default.
• W3213698701 cites W2903264198 @default.
• W3213698701 cites W2997202530 @default.
• W3213698701 cites W2999417355 @default.
• W3213698701 cites W3009494702 @default.
• W3213698701 cites W3012313889 @default.
• W3213698701 cites W3022943852 @default.
• W3213698701 cites W3038501750 @default.
• W3213698701 cites W3089990384 @default.
• W3213698701 cites W3193763885 @default.
• W3213698701 cites W3196648022 @default.
• W3213698701 cites W36141288 @default.
• W3213698701 cites W4243735624 @default.
• W3213698701 doi "https://doi.org/10.3390/cancers13225775" @default.
• W3213698701 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8616444" @default.
• W3213698701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34830928" @default.
• W3213698701 hasPublicationYear "2021" @default.
• W3213698701 type Work @default.
• W3213698701 sameAs 3213698701 @default.
• W3213698701 citedByCount "3" @default.
• W3213698701 countsByYear W32136987012022 @default.
• W3213698701 crossrefType "journal-article" @default.
• W3213698701 hasAuthorship W3213698701A5030752637 @default.
• W3213698701 hasAuthorship W3213698701A5032796168 @default.
• W3213698701 hasAuthorship W3213698701A5042365463 @default.

• next